To the Editor A recent Viewpoint recommended that the US Food and Drug Administration (FDA) move fast-acting β2-agonist (FABA) inhalers to over-the-counter (OTC) status, citing the current availability of OTC inhaled epinephrine. Although appreciating the intention of improving access to approved therapies for relief of acute asthma symptoms, we believe this recommendation merits a full consideration of risks and benefits.
